key: cord-0936981-d21mispg
authors: Venkitakrishnan, Rajesh; Augustine, Jolsana; Ramachandran, Divya; Cleetus, Melcy
title: Casirivimab - Imdevimab in Covid 19 – early Indian experience
date: 2021-10-04
journal: Indian J Tuberc
DOI: 10.1016/j.ijtb.2021.09.014
sha: 76a52c3ac1d9e679a61b173d690912316b5a4957
doc_id: 936981
cord_uid: d21mispg

nan

We share the clinical data and results of our first 29 patients who in whom the agent was administered. The drug was offered to 146 patients of whom 29 decided to go ahead with administration of the agent. Reasons for opting out included cost of therapy and lack of concern towards disease progression. The patients included out patients and covid patients admitted for reasons other than covid. The drug was administered in the Covid 19 in-patient ward (for out-patients also) and they were observed for a period of four hours for any adverse reactions. Of the patients in whom the drug was used, more than 50% had two indications. 

China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China

Coronavirus Disease 2019 Case Surveillance -United States

Underlying Medical Conditions Associated with High Risk for Severe COVID-19: Information for Healthcare Providers

BLAZE-1 Investigators. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Antibody Cocktail Clinical Outcomes Study in Covid-19 Outpatients

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Risk factors for disease progression and worse outcomes in Covid 19 are increasingly being spelt out

Subgroup of patients at risk of progression merit monoclonal antibody therapy with casirivimab and imdevimab